Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design

Rationale Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation. Aim The ATTICUS randomized trial is designed to determine whet...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:International journal of stroke Ročník 12; číslo 9; s. 985 - 990
Hlavní autori: Geisler, Tobias, Poli, Sven, Meisner, Christoph, Schreieck, Juergen, Zuern, Christine S, Nägele, Thomas, Brachmann, Johannes, Jung, Werner, Gahn, Georg, Schmid, Elisabeth, Bäezner, Hansjörg, Keller, Timea, Petzold, Gabor C, Schrickel, Jan-Wilko, Liman, Jan, Wachter, Rolf, Schön, Frauke, Schabet, Martin, Lindner, Alfred, Ludolph, Albert C, Kimmig, Hubert, Jander, Sebastian, Schlegel, Uwe, Gawaz, Meinrad, Ziemann, Ulf
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.12.2017
Predmet:
Aspirin - therapeutic use
Brain - diagnostic imaging
Brain - drug effects
Embolism - diagnostic imaging
Embolism - drug therapy
Factor Xa Inhibitors - therapeutic use
Fibrinolytic Agents - therapeutic use
Humans
Pyrazoles - therapeutic use
Pyridones - therapeutic use
Research Design
Secondary Prevention
Stroke - diagnostic imaging
Stroke - drug therapy
atrial fibrillation
NOAC
aspirin
ESUS
apixaban
intracardiac monitor
stroke
ISSN:1747-4949
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Rationale Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation. Aim The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for prevention of new ischemic lesions documented by brain magnetic resonance imaging within 12 months after index stroke. Design Prospective, randomized, blinded, parallel-group, open-label, German multicenter phase III trial in approximately 500 patients with embolic stroke of undetermined source. A key inclusion criterion is the presence or the planned implantation of an insertable cardiac monitor. Patients are 1:1 randomized to apixaban or acetylsalicylic acid and treated for a 12-month period. It is an event-driven trial aiming for core-lab adjudicated primary outcome events. Study outcomes The primary outcome is the occurrence of at least one new ischemic lesion identified by axial T2-weighted FLAIR magnetic resonance imaging and/or axial DWI magnetic resonance imaging at 12 months when compared with the baseline magnetic resonance imaging. Key secondary outcomes are the combination of recurrent ischemic strokes, hemorrhagic strokes, systemic embolism; combination of MACE including recurrent stroke, myocardial infarction, and cardiovascular death and combination of major and clinically relevant non-major bleeding defined according to ISTH, and change of cognitive function and quality of life (EQ-5D, Stroke Impact Scale). Discussion Embolic stroke of undetermined source is caused by embolic disease and associated with a high risk of recurrent ischemic strokes and clinically silent cerebral ischemic lesions. ATTICUS will investigate the impact of atrial fibrillation detected by insertable cardiac monitor and the effects of early anticoagulation with apixaban compared with antiplatelet therapy with acetylsalicylic acid on the incidence of new ischemic lesion after embolic stroke of undetermined source.
AbstractList Rationale Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation. Aim The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for prevention of new ischemic lesions documented by brain magnetic resonance imaging within 12 months after index stroke. Design Prospective, randomized, blinded, parallel-group, open-label, German multicenter phase III trial in approximately 500 patients with embolic stroke of undetermined source. A key inclusion criterion is the presence or the planned implantation of an insertable cardiac monitor. Patients are 1:1 randomized to apixaban or acetylsalicylic acid and treated for a 12-month period. It is an event-driven trial aiming for core-lab adjudicated primary outcome events. Study outcomes The primary outcome is the occurrence of at least one new ischemic lesion identified by axial T2-weighted FLAIR magnetic resonance imaging and/or axial DWI magnetic resonance imaging at 12 months when compared with the baseline magnetic resonance imaging. Key secondary outcomes are the combination of recurrent ischemic strokes, hemorrhagic strokes, systemic embolism; combination of MACE including recurrent stroke, myocardial infarction, and cardiovascular death and combination of major and clinically relevant non-major bleeding defined according to ISTH, and change of cognitive function and quality of life (EQ-5D, Stroke Impact Scale). Discussion Embolic stroke of undetermined source is caused by embolic disease and associated with a high risk of recurrent ischemic strokes and clinically silent cerebral ischemic lesions. ATTICUS will investigate the impact of atrial fibrillation detected by insertable cardiac monitor and the effects of early anticoagulation with apixaban compared with antiplatelet therapy with acetylsalicylic acid on the incidence of new ischemic lesion after embolic stroke of undetermined source.
Author Wachter, Rolf
Jung, Werner
Schrickel, Jan-Wilko
Geisler, Tobias
Schmid, Elisabeth
Ludolph, Albert C
Gawaz, Meinrad
Schlegel, Uwe
Jander, Sebastian
Bäezner, Hansjörg
Lindner, Alfred
Meisner, Christoph
Ziemann, Ulf
Petzold, Gabor C
Gahn, Georg
Liman, Jan
Keller, Timea
Schön, Frauke
Zuern, Christine S
Poli, Sven
Schabet, Martin
Nägele, Thomas
Schreieck, Juergen
Kimmig, Hubert
Brachmann, Johannes
Author_xml – sequence: 1
  givenname: Tobias
  surname: Geisler
  fullname: Geisler, Tobias
  organization: 1 Department of Cardiology, German Heart Competence Centre, Tübingen, Germany
– sequence: 2
  givenname: Sven
  surname: Poli
  fullname: Poli, Sven
  organization: 2 Department of Neurology and Stroke, Tübingen Center of Neurovascular Diseases, Tübingen, Germany
– sequence: 3
  givenname: Christoph
  surname: Meisner
  fullname: Meisner, Christoph
  organization: 3 Eberhard-Karl University of Tübingen, Institute for Clinical Epidemiology and Applied Biometry, Tübingen, Germany
– sequence: 4
  givenname: Juergen
  surname: Schreieck
  fullname: Schreieck, Juergen
  organization: 1 Department of Cardiology, German Heart Competence Centre, Tübingen, Germany
– sequence: 5
  givenname: Christine S
  surname: Zuern
  fullname: Zuern, Christine S
  organization: 1 Department of Cardiology, German Heart Competence Centre, Tübingen, Germany
– sequence: 6
  givenname: Thomas
  surname: Nägele
  fullname: Nägele, Thomas
  organization: 4 Department of Neuroradiology, University of Tübingen, Tübingen, Germany
– sequence: 7
  givenname: Johannes
  surname: Brachmann
  fullname: Brachmann, Johannes
  organization: 5 Department of Internal Medicine II, Cardiology, Angiology and Pneumology, Klinikum Coburg GmbH, Coburg, Germany
– sequence: 8
  givenname: Werner
  surname: Jung
  fullname: Jung, Werner
  organization: 6 Department of Internal Medicine III, Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany
– sequence: 9
  givenname: Georg
  surname: Gahn
  fullname: Gahn, Georg
  organization: 7 Department Neurologie, Klinikum Karlsruhe, Karlsruhe, Germany
– sequence: 10
  givenname: Elisabeth
  surname: Schmid
  fullname: Schmid, Elisabeth
  organization: 8 Department of Neurology, Klinikum Stuttgart, Stuttgart, Germany
– sequence: 11
  givenname: Hansjörg
  surname: Bäezner
  fullname: Bäezner, Hansjörg
  organization: 8 Department of Neurology, Klinikum Stuttgart, Stuttgart, Germany
– sequence: 12
  givenname: Timea
  surname: Keller
  fullname: Keller, Timea
  organization: 1 Department of Cardiology, German Heart Competence Centre, Tübingen, Germany
– sequence: 13
  givenname: Gabor C
  surname: Petzold
  fullname: Petzold, Gabor C
  organization: 10 German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
– sequence: 14
  givenname: Jan-Wilko
  surname: Schrickel
  fullname: Schrickel, Jan-Wilko
  organization: 11 Department of Medicine-Cardiology, University Hospital Bonn, Bonn, Germany
– sequence: 15
  givenname: Jan
  surname: Liman
  fullname: Liman, Jan
  organization: 12 Department of Neurology, University of Göttingen, Göttingen, Germany
– sequence: 16
  givenname: Rolf
  surname: Wachter
  fullname: Wachter, Rolf
  organization: 13 Department of Cardiology and Pneumology, Göttingen University Medical Center, German Cardiovascular Research Center (DZHK), partner site Göttingen, Germany
– sequence: 17
  givenname: Frauke
  surname: Schön
  fullname: Schön, Frauke
  organization: 14 Department of Neurology, Klinikum Ludwigsburg, Ludwigsburg, Germany
– sequence: 18
  givenname: Martin
  surname: Schabet
  fullname: Schabet, Martin
  organization: 14 Department of Neurology, Klinikum Ludwigsburg, Ludwigsburg, Germany
– sequence: 19
  givenname: Alfred
  surname: Lindner
  fullname: Lindner, Alfred
  organization: 15 Department of Neurology, Marienhospital Stuttgart, Stuttgart, Germany
– sequence: 20
  givenname: Albert C
  surname: Ludolph
  fullname: Ludolph, Albert C
  organization: 16 Department of Neurology, University of Ulm, Ulm, Germany
– sequence: 21
  givenname: Hubert
  surname: Kimmig
  fullname: Kimmig, Hubert
  organization: 18 Department of Neurology, University Freiburg, Freiburg, Germany
– sequence: 22
  givenname: Sebastian
  surname: Jander
  fullname: Jander, Sebastian
  organization: 19 Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany
– sequence: 23
  givenname: Uwe
  surname: Schlegel
  fullname: Schlegel, Uwe
  organization: 20 Department of Neurology, Knappschaftskrankenhaus, Klinikum der Ruhr-Universität Bochum, Bochum, Germany
– sequence: 24
  givenname: Meinrad
  surname: Gawaz
  fullname: Gawaz, Meinrad
  organization: 1 Department of Cardiology, German Heart Competence Centre, Tübingen, Germany
– sequence: 25
  givenname: Ulf
  surname: Ziemann
  fullname: Ziemann, Ulf
  organization: 2 Department of Neurology and Stroke, Tübingen Center of Neurovascular Diseases, Tübingen, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27881833$$D View this record in MEDLINE/PubMed
BookMark eNo1kM1LwzAchoMo7kPvniTHeZgmTdok3sbwCwaCbueStL9KtE1mkorzr7fDeXrhfV6ewztBx847QOiCkmtKhbihgguuGKFFISmh6giN99WcK65GaBLjOyE8F6w4RaNMSEklY2P0tdjab220w40POAXQqQOXsG8wdMa3tsIxBf8B-6Z3NSQInXVQ4-j7UAGeLdbrp-XmFQftat_ZnwGlYHV7dYtfdLLe6RbwwAZPX-9wDdG-uTN00ug2wvkhp2hzf7dePs5Xzw9Py8VqXnGepzk0GrjmLG9yJrgxyuhMSZYpRWVuCDFKMdlQKVhFRAGmKbRusgqKjNY0VyKbotmfdxv8Zw8xlZ2NFbStduD7WFLJmSoUYcUwvTxMe9NBXW6D7XTYlf9fZb-x42wA
CitedBy_id crossref_primary_10_3389_fneur_2020_588151
crossref_primary_10_1055_s_0040_1715831
crossref_primary_10_1016_j_jelectrocard_2019_11_050
crossref_primary_10_1080_14779072_2020_1733977
crossref_primary_10_1017_cjn_2022_66
crossref_primary_10_1161_STROKEAHA_121_034498
crossref_primary_10_1007_s15027_018_1405_0
crossref_primary_10_1161_CIRCRESAHA_120_316341
crossref_primary_10_1007_s00115_019_00788_w
crossref_primary_10_1016_j_neurol_2022_01_016
crossref_primary_10_1111_ane_12934
crossref_primary_10_1002_clc_23673
crossref_primary_10_1177_17474930211009847
crossref_primary_10_1056_NEJMoa1802686
crossref_primary_10_3389_fneur_2021_679320
crossref_primary_10_3389_fneur_2022_982926
crossref_primary_10_1161_JAHA_121_021045
crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_05_023
crossref_primary_10_1016_j_jfma_2020_05_026
crossref_primary_10_1212_WNL_0000000000007002
crossref_primary_10_1161_STROKEAHA_118_024160
crossref_primary_10_1161_STROKEAHA_121_035208
crossref_primary_10_1007_s00115_020_00893_1
crossref_primary_10_1007_s00117_024_01411_z
crossref_primary_10_1007_s11831_025_10406_5
crossref_primary_10_3390_jcm11195740
crossref_primary_10_1007_s00392_021_01834_x
crossref_primary_10_3389_fcvm_2022_942385
crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_104390
crossref_primary_10_1182_blood_2019000820
crossref_primary_10_5604_01_3001_0015_7296
crossref_primary_10_1016_j_jacc_2024_10_100
crossref_primary_10_1016_j_medcli_2020_09_024
crossref_primary_10_1161_STROKEAHA_120_033217
crossref_primary_10_1016_j_ejim_2021_08_002
crossref_primary_10_1177_1747493017724624
crossref_primary_10_1161_STROKEAHA_118_023281
crossref_primary_10_1007_s15005_019_0168_1
crossref_primary_10_1016_j_jjcc_2018_03_002
crossref_primary_10_3390_life11050448
crossref_primary_10_1055_a_1336_0576
crossref_primary_10_3390_jcm13133819
crossref_primary_10_36290_vnl_2021_001
crossref_primary_10_1007_s11239_019_01951_5
crossref_primary_10_1016_j_jacc_2019_06_039
crossref_primary_10_1212_WNL_0000000000008556
crossref_primary_10_1055_a_2465_8151
crossref_primary_10_1111_jce_15440
crossref_primary_10_5937_arhfarm2005269J
crossref_primary_10_1016_j_clineuro_2017_05_019
crossref_primary_10_1161_STROKEAHA_119_028643
crossref_primary_10_1093_eurheartj_ehaa612
crossref_primary_10_1160_TH17_08_0592
crossref_primary_10_1177_23969873221076971
crossref_primary_10_1016_j_jstrokecerebrovasdis_2018_09_039
crossref_primary_10_1016_j_medcle_2020_09_021
crossref_primary_10_1161_CIRCULATIONAHA_120_049768
crossref_primary_10_3389_fneur_2020_00653
crossref_primary_10_1007_s15005_018_2792_6
crossref_primary_10_1097_WCO_0000000000001009
crossref_primary_10_2459_JCM_0000000000001023
crossref_primary_10_1177_1941874420934333
crossref_primary_10_1007_s11940_019_0571_4
crossref_primary_10_1007_s13311_023_01383_3
crossref_primary_10_1136_heartjnl_2020_317455
crossref_primary_10_1136_practneurol_2018_002089
crossref_primary_10_1007_s10072_018_3322_5
crossref_primary_10_1177_1747493018799981
crossref_primary_10_1007_s40265_018_0912_8
crossref_primary_10_1161_STROKEAHA_120_029305
crossref_primary_10_3389_fneur_2022_952462
crossref_primary_10_1002_ana_25825
crossref_primary_10_1007_s11936_021_00952_z
crossref_primary_10_1007_s11936_019_0786_4
crossref_primary_10_1007_s11940_022_00730_7
crossref_primary_10_1016_j_ijcard_2023_131215
crossref_primary_10_1016_j_medcli_2018_01_024
crossref_primary_10_1016_j_maturitas_2019_01_004
crossref_primary_10_1016_j_nrleng_2019_10_008
crossref_primary_10_1136_bmjopen_2019_031716
crossref_primary_10_1038_s41582_022_00663_4
crossref_primary_10_1007_s15202_019_2294_5
crossref_primary_10_1016_j_medcle_2018_05_041
crossref_primary_10_1007_s10554_022_02779_6
crossref_primary_10_1161_CIRCRESAHA_121_319947
crossref_primary_10_1016_j_ancard_2021_10_006
crossref_primary_10_1016_j_jstrokecerebrovasdis_2019_04_022
crossref_primary_10_1002_ana_26545
crossref_primary_10_4103_0028_3886_333477
crossref_primary_10_1007_s11910_025_01447_1
crossref_primary_10_1080_14656566_2022_2071125
crossref_primary_10_1007_s00392_023_02283_4
crossref_primary_10_1080_14656566_2022_2149323
crossref_primary_10_1111_ene_15356
crossref_primary_10_1097_MD_0000000000013830
crossref_primary_10_1007_s00392_019_01501_2
crossref_primary_10_1016_j_ejvs_2023_03_042
crossref_primary_10_1055_s_0041_1726403
crossref_primary_10_2478_jtim_2022_0032
crossref_primary_10_1161_STR_0000000000000375
crossref_primary_10_1016_j_cjca_2022_10_017
crossref_primary_10_1016_j_amjcard_2023_06_002
crossref_primary_10_1055_s_0040_1721665
crossref_primary_10_1001_jamanetworkopen_2018_2953
crossref_primary_10_7326_M23_3136
crossref_primary_10_1016_j_jns_2017_09_027
crossref_primary_10_1161_STROKEAHA_121_034778
crossref_primary_10_3390_jcm9041134
crossref_primary_10_1177_23969873241229612
crossref_primary_10_1177_1747493019826363
crossref_primary_10_2478_jtim_2021_0055
crossref_primary_10_3390_ijerph18168679
crossref_primary_10_1212_WNL_0000000000007827
crossref_primary_10_1016_j_neurol_2020_04_015
crossref_primary_10_1212_WNL_0000000000007823
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7U8
7X8
C1K
JXQ
DOI 10.1177/1747493016681019
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
TOXLINE
MEDLINE - Academic
Environmental Sciences and Pollution Management
Toxline
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
TOXLINE
MEDLINE - Academic
Environmental Sciences and Pollution Management
DatabaseTitleList MEDLINE
TOXLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1747-4949
EndPage 990
ExternalDocumentID 27881833
Genre Clinical Trial, Phase III
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-TM
.3N
.GA
.Y3
05W
0R~
10A
1OC
26-
29J
31~
4.4
50Y
50Z
52M
52O
52S
52T
52W
53G
54M
5GY
5HH
5VS
702
7PT
8-0
8-1
8-3
8-4
8-5
930
A01
A03
AABMB
AACMV
AADUE
AAEVG
AAEWN
AAGMC
AAHHS
AAJPV
AAKGS
AANHP
AAONW
AAQXI
AARDL
AARIX
AATAA
AATBZ
AAUAS
ABAWP
ABCCA
ABCJG
ABEIX
ABFWQ
ABJNI
ABKRH
ABLUO
ABNCE
ABPNF
ABPVW
ABQNX
ABQXT
ABRHV
ABUJY
ABVFX
ABXGC
ACARO
ACBWZ
ACCFJ
ACDSZ
ACDXX
ACFEJ
ACGFO
ACGFS
ACGZU
ACJER
ACJTF
ACLFY
ACOFE
ACOXC
ACPRK
ACROE
ACRPL
ACSIQ
ACTQU
ACUAV
ACUIR
ACXKE
ACXMB
ACXQS
ACYXJ
ADBBV
ADIZJ
ADNMO
ADNON
ADRRZ
ADVBO
ADZOD
ADZZY
AECGH
AEEZP
AEIMD
AENEX
AEPTA
AEQDE
AEQLS
AESZF
AEUHG
AEUIJ
AEWDL
AEWHI
AEXNY
AFBPY
AFEET
AFKRG
AFMOU
AFQAA
AFUIA
AGHKR
AGKLV
AGNHF
AGPXR
AGWFA
AHDMH
AHMBA
AIOMO
AIWBW
AJAOE
AJBDE
AJUZI
AJXAJ
ALAGY
ALKWR
ALMA_UNASSIGNED_HOLDINGS
ALTZF
AMBMR
AMCVQ
ARTOV
ATUGU
AUTPY
AYAKG
AZBYB
B8M
BAFTC
BBRGL
BDDNI
BDRZF
BFHJK
BKIIM
BKSCU
BPACV
BROTX
BRXPI
BSEHC
BWJAD
CAG
CDWPY
CFDXU
CGR
COF
CS3
CUY
CVF
D-6
D-7
D-E
D-F
DC-
DC.
DCZOG
DOPDO
DPXWK
DU5
DV7
EBS
ECM
EIF
EJD
EMOBN
ESX
F00
F01
F04
F21
F5P
FEDTE
FHBDP
G-S
G.N
GODZA
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H.X
H13
HF~
HOLLA
HVGLF
HZ~
J8X
K.F
LH4
LP6
LP7
LW6
M4V
MK4
N04
N05
NF~
NPM
O9-
OIG
OVD
P2P
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
QB0
R.K
ROL
RX1
SAUOL
SCNPE
SFC
SHG
SPQ
SPV
SUPJJ
TEORI
UB1
V8K
W8V
W99
WYUIH
XG1
ZONMY
ZPPRI
ZRKOI
ZSSAH
~IA
~WT
7U8
7X8
AAPII
ABIDT
ABJZC
ADEBD
AJGYC
AJHME
AJVBE
C1K
JXQ
SASJQ
ID FETCH-LOGICAL-c445t-efae4a435f5374bb9ba2983299185b00b9938f1873c076ebf6aaf2ce621d15972
IEDL.DBID 7X8
ISICitedReferencesCount 123
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000414307100015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
IngestDate Sun Sep 28 10:12:12 EDT 2025
Wed Feb 19 02:43:40 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords atrial fibrillation
NOAC
aspirin
ESUS
apixaban
intracardiac monitor
stroke
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c445t-efae4a435f5374bb9ba2983299185b00b9938f1873c076ebf6aaf2ce621d15972
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://resolver.sub.uni-goettingen.de/purl?gro-2/77381
PMID 27881833
PQID 1843969036
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_1843969036
pubmed_primary_27881833
PublicationCentury 2000
PublicationDate 2017-12-01
PublicationDateYYYYMMDD 2017-12-01
PublicationDate_xml – month: 12
  year: 2017
  text: 2017-12-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle International journal of stroke
PublicationTitleAlternate Int J Stroke
PublicationYear 2017
SSID ssj0045736
Score 2.504724
Snippet Rationale Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 985
SubjectTerms Aspirin - therapeutic use
Brain - diagnostic imaging
Brain - drug effects
Embolism - diagnostic imaging
Embolism - drug therapy
Factor Xa Inhibitors - therapeutic use
Fibrinolytic Agents - therapeutic use
Humans
Pyrazoles - therapeutic use
Pyridones - therapeutic use
Research Design
Secondary Prevention
Stroke - diagnostic imaging
Stroke - drug therapy
Title Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design
URI https://www.ncbi.nlm.nih.gov/pubmed/27881833
https://www.proquest.com/docview/1843969036
Volume 12
WOSCitedRecordID wos000414307100015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxfpk3IvigD0GXpk3ji4zhUHBj6AZ7G0mawJC1c51D_PWepN30SQRf-tBSKMm5fDnn9PsQulAQ8gJbi0mQhJI4jSuihGQkFDrh4OiSW0-Z_8Tb7bjfF52y4JaXY5XzmOgDdZJpVyO_drokAo5yQXQ3fiNONcp1V0sJjWVUCQDKOMfk_UUXgYX8Z2vyGsA3ZwIsOnIkXLVfQKVPLs3N_37WFtooYSWuF3awjZZMuoPWWmXjfBfN6uPhh1QyxQBS8WK6HGcWm5Fy3MA4n06yV-PuuP_KiiEZk-Ciuo8v693uY6P3giG3Jdlo-AmPvOLH1S1-LguKBsMz7AlrceInQ_ZQr3nfbTyQUnKBaMbCKTFWGiYBQtkw4EwpoSQV4PSAIuMQPFQBnIlha3mgb3hklI2ktFSbiNYSAEac7qOVNEvNIcIqVBAbJJVSK6YhJ4aaRtYIDQc0FXNTRefzFR2ASbs-hUxN9p4Pvte0ig6KbRmMC-6NAXX093EQHP3h7WO0Tl0S9sMnJ6hiwaHNKVrVs-kwn5x5W4Fru9P6ApvBy6s
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Apixaban+for+treatment+of+embolic+stroke+of+undetermined+source+%28ATTICUS+randomized+trial%29%3A+Rationale+and+study+design&rft.jtitle=International+journal+of+stroke&rft.au=Geisler%2C+Tobias&rft.au=Poli%2C+Sven&rft.au=Meisner%2C+Christoph&rft.au=Schreieck%2C+Juergen&rft.date=2017-12-01&rft.eissn=1747-4949&rft.volume=12&rft.issue=9&rft.spage=985&rft_id=info:doi/10.1177%2F1747493016681019&rft_id=info%3Apmid%2F27881833&rft_id=info%3Apmid%2F27881833&rft.externalDocID=27881833